Newsfeeds - Spark Newswire

1 minute read

FDA Casts Doubts Over Roche’s Polivy Label Expansion For Untreated Lymphoma Setting

Today, 8:40 PM

Today, the FDA Oncologic Drugs Advisory Committee is discussing the supplemental marketing application for Polivy (polatuzumab vedotin-piiq) plus Rituxan (rituximab)…

RHHBF

1 minute read

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo

By Vandana Singh

Today, 8:40 PM

Exelixis Inc (NASDAQ:EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 is…

EXEL

1 minute read

Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines

By Vandana Singh

Today, 8:40 PM

Blueprint Medicines Corporation (NASDAQ:BPMC) will regain global commercialization and development rights to Gavreto (pralsetinib), excluding Greater China, following a…

BPMC

1 minute read

New Data Shows Roche’s Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder

By Vandana Singh

Today, 8:40 PM

Roche Holdings AG (OTC:RHHBY) announced new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab) in macular…

REGN

1 minute read

Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition

By Vandana Singh

Today, 8:40 PM

Roche Holdings AG (OTC:RHHBY) has announced results from the global phase 3 COMMODORE 2 study, evaluating the efficacy and…

RHHBF

1 minute read

Genentech’s Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer

By Vandana Singh

Today, 8:40 PM

Genentech, a unit of Roche Holdings AG (OTC:RHHBY), announced that the Phase 3 IMbrave050 study met its primary endpoint of recurrence-free survival…

RHHBF

1 minute read

Roche’s Follicular Lymphoma Therapy Scores FDA Approval

By Vandana Singh

Today, 8:40 PM

The FDA approved Roche Holding AG (OTC:RHHBY) unit Genentech’s Lunsumio (mosunetuzumab-axgb) for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more…

BIIB

1 minute read

Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates

By Vandana Singh

Today, 8:40 PM

Roche Holdings AG (OTC:RHHBY) announced that updated clinical data for its CD20xCD3 T-cell engaging bispecific antibodies, including five oral presentations, were…

RHHBF

1 minute read

Exelixis’ Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting

By Vandana Singh

Today, 8:40 PM

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

EXEL

4 minute read

Mirati Plays Catch-Up With Amgen, Gilead’s 2nd Try With AIDS Drug, Cytokinetics’ Adcom Test And More: Key Nov FDA Decisions For Biotech Investors

By Shanthi Rexaline

Today, 8:40 PM

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

AMGN